Irbesartan + Hidroclorotiazida Tetrafarma

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Tetrafarma, is an Angiotensin II receptor blocker presented as a fixed‑dose oral tablet for oral use. It is combined with hydrochlorothiazide to treat hypertension in adult patients. GNH USA supplies Irbesartan + Hidroclorotiazida Tetrafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive medication that lowers elevated blood pressure through vascular relaxation and diuresis.

Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. Secondary hypertension: assists in controlling blood pressure when the cause is identifiable, such as renal disease. Hypertension with fluid retention: provides combined vasodilatory and diuretic effects for patients needing volume reduction.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia - Angioedema or severe allergic reaction - Liver enzyme abnormalities - Significant hypotension leading to syncope

Before initiating therapy, consider the following precautions: - Monitor renal function: assess serum creatinine and eGFR prior to and during treatment. - Check electrolytes: especially sodium and potassium levels, adjusting therapy as needed. - Use with caution in severe hepatic impairment: dose adjustments may be required. - Caution in diabetic patients: monitor blood glucose as diuretic effect may affect glycemic control. - Pregnancy and lactation: safety not established; avoid unless clearly indicated. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or aliskiren in pregnancy: increased fetal toxicity. - Lithium: elevated lithium concentrations. - NSAIDs: may blunt antihypertensive effect. - Cyclosporine: may raise serum creatinine.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering. - Antidiabetic agents: potential enhancement of hypoglycemia. - Tricyclic antidepressants: may increase orthostatic hypotension. - Alcohol: can exacerbate dizziness and hypotension.